Purpose

To determine the difference in time to recovery and healing of monkey pox lesions between people receiving Tecovirimat and those receiving placebo. People with severe cases of monkeypox will receive Tecovirimat and not placebo.

Category

IRB Number
20220654HU
NCT Number
-
Open to Enrollment
Yes
Sponsor
-



Study Contact

Local Recruitment Point of Contact
Thomas Patterson
(210) 567-4666
patterson@uthscsa.edu

Local Recruitment Point of Contact
Robin Tragus
(210) 567-5262
tragus@uthscsa.edu

Principal Investigator
Thomas Patterson

Regulatory Point of Contact
Thomas Patterson
(210) 567-4666
patterson@uthscsa.edu

Regulatory Point of Contact
Irma Scholler
+1 (210) 450-3150
scholler@uthscsa.edu

Regulatory Point of Contact
Robin Tragus
(210) 567-5262
tragus@uthscsa.edu



Eligibility

Eligible Ages
18-99
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

    Illness < 14 days before study entry, have at least 1 active (not scabbed) lesion

Exclusion Criteria

    Illness < 14 days before study entry, have at least 1 active (not scabbed) lesion


Study Design

Arm Groups